难治性室性心律失常心脏立体定向放射消融靶区变异及其决定因素系统综述与汇总分析
该系统综述汇总分析检索MEDLINE与EMBASE截至2025年1月31日,纳入13项研究共126例接受心脏立体定向心律失常放射消融的难治性室性心律失常患者。结果显示计划靶区与临床靶区体积比汇总值为2.8,治疗实施不确定性与心肺运动相关外扩对最终治疗体积的贡献相当。研究提示现有团队间治疗体积生成存在高度变异。
要点
- 心脏立体定向心律失常放射消融缺乏边界选择推荐,团队间治疗体积差异很大。
- 计划靶区与临床靶区体积比汇总为2.8,提示总体外扩明显。
- 治疗实施不确定性与心肺运动所致外扩对最终体积贡献相近。
核心结论
- 难治性室性心律失常心脏立体定向心律失常放射消融的治疗体积生成即使在专家团队间也存在高度变异,最小与最大报告的平均计划靶区相差约九倍。
- 与治疗实施不确定性相关的边界外扩对最终治疗体积的贡献,似乎与心肺运动相关边界外扩同样重要。
研究设计与样本
- 本研究为系统综述与汇总分析,检索MEDLINE和EMBASE数据库,截至2025年1月31日,纳入描述心脏立体定向心律失常放射消融治疗难治性室性心律失常的研究。
- 共检索到1020篇文献,13项研究符合纳入标准,纳入126例接受心脏立体定向心律失常放射消融治疗的室性心律失常患者。
- 提取的指标包括临床靶区、内靶区和计划靶区体积,并以计划靶区/临床靶区、内靶区/临床靶区、计划靶区/内靶区体积比评估体积外扩程度。
主要发现
- 汇总的总外扩比(计划靶区/临床靶区比值)为2.8(95% CI:2.0–3.6,I²=73%)。
- 与治疗实施不确定性相关的汇总体积外扩比(计划靶区/内靶区比值)为1.9(95% CI:1.7–2.2,I²=12%)。
- 与心肺运动边界相关的汇总体积外扩比(内靶区/临床靶区比值)为1.9(95% CI:1.4–2.3,I²=36.5%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Cardiac stereotactic arrhythmia radioablation (STAR) has emerged as a promising alternative for patients with refractory ventricular arrhythmias (VAs). However, the absence of recommendations for margin selection may lead to considerable differences in the treatment plan generation between teams. Objectives This systematic review and pooled analysis aimed at determining the inter-study variability in target volumes as well as the main drivers of the final treated volume during STAR for refractory VAs. Methods MEDLINE and EMBASE databases were searched until January 31, 2025, to identify all studies describing the use of STAR for treating refractory VAs. Treatment volumes were extracted including clinical target volume (CTV), internal target volume (ITV), and planning target volume (PTV). Volume expansion was assessed using PTV/CTV, ITV/CTV and PTV/ITV ratios. Results A total of 1020 references were retrieved, of which 13 studies met the inclusion criteria, representing 126 patients treated with STAR for VAs. In aggregates, the pooled total volume expansion (PTV/CTV ratio) was 2.8 (95% CI: 2.0–3.6, I 2 = 73%), the pooled volume expansion related to treatment delivery uncertainties (PTV/ITV ratio) was 1.9 (95% CI: 1.7–2.2, I 2 = 12%) and the pooled volume expansion related to cardiorespiratory margins (ITV/CTV ratio) was 1.9 (95% CI: 1.4–2.3, I 2 = 36.5%). Conclusion Generation of the treatment volume in STAR for refractory VA is subject to high variability even among expert teams, with a ninefold difference observed between the smallest and largest reported average PTV. Margins related to uncertainties in treatment delivery seem to contribute as much as margins related to cardiorespiratory movement in determining the final treatment volume. PROSPERO registration: CRD42024580242.
引用
- Journal of Cardiovascular Electrophysiology:Variability and Main Determinants of Planning Target Volume During Cardiac Stereotactic Radioablation for Refractory Ventricular Arrhythmias: A Systematic Review and Pooled Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。